Emerging ocular biomarkers of Alzheimer disease
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Interest in reliable biomarkers of Alzheimer disease, the leading cause of dementia, has been fuelled by challenges in diagnosing the disease and monitoring disease progression as well as the response to therapy. A range of ocular manifestations of Alzheimer disease, including retinal and lens amyloid‐beta accumulation, retinal nerve fiber layer loss, and retinal vascular changes, have been proposed as potential biomarkers of the disease. Herein, we examine the evidence regarding the potential value of these ocular biomarkers of Alzheimer disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 2×
“Brain vasogenic edema occurred in a dose-dependent manner and was observed in 47% of subjects treated with the highest dose of the antibody.(11) Long-term extension of the study and 2 phase III clinical trials are underway.”
BackgroundPreclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · cited 1×
“Positron emission tomography studies have demonstrated that amyloid accumulation predates the onset of clinical symptoms by as long as 15 to 20 years, highlighting the potential for amyloid imaging in preclinical diagnosis of the disease.(4,5) Unfortunately, PET scans are costly, difficult to access, involve the use o…”
BackgroundKoronyo-Hamaoui, M., Koronyo, Y., Ljubimov, A. V., Miller, C. A., Ko, M. K., Black, K. L., Schwartz, M., & Farkas, D. L. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.06.020 · Cited by 672
Testing the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550
Johnson, L. V., Leitner, W. P., Rivest, A. J., Staples, M. K., Radeke, M. J., & Anderson, D. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192203399 · Cited by 447
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434 · cited 1×
“Cerebrospinal fluid biomarkers, including Aβ and tau, have value in confirming a clinical diagnosis of AD, but alone they have limited sensitivity and specificity and necessitate lumbar puncture, an invasive procedure that is not appropriate for screening at a population level.(5,6) It has been postulated that diagnos…”
BackgroundPhase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370 · cited 2×
“When data for all trial participants with mild AD were pooled, 3 of 6 prespecified endpoints were met and cognitive decline was slowed by 34%.(10) A more recent double blind placebo-controlled phase Ib randomized trial of monthly infusions of aducanumab, a human monoclonal antibody with specificity for aggregated Aβ,…”
BackgroundAmyloid-β Deposits Lead to Retinal Degeneration in a Mouse Model of Alzheimer Disease
Ning, A., Cui, J., To, E., Ashe, K. H., & Matsubara, J. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-1849 · Cited by 303
Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease
Frost, S., Kanagasingam, Y., Sohrabi, H., Vignarajan, J., Bourgeat, P., Salvado, O., Villemagne, V, Rowe, C. C., Lance Macaulay, S., Szoeke, C., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.150 · Cited by 297
Cited by
How important is tryptophan in human health?
Kałużna-Czaplińska, J., Gątarek, P., Chirumbolo, S., Chartrand, M. S., & Bjørklund, G. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1357534 · Cited by 333
“This disease affects approximately 35.6 million people worldwide in 2010 and by the year 2050 estimated 115 million people (Van Wijngaarden et al., 2017).”
BackgroundInfluentialHadoux, X., Hui, F., Lim, J. K. H., Masters, C. L., Pébay, A., Chevalier, S., Ha, J., Loi, S., Fowler, C. J., Rowe, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12242-1 · Cited by 304
Self-citationAstrocytic TSPO upregulation appears before microglial TSPO in Alzheimer’s disease
Tournier, B. B., Tsartsalis, S., Ceyzériat, K., Fraser, B. H., Grégoire, M.-C., Kövari, E., & Millet, P. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200136 · Cited by 65
Amyloid precursor protein‐mediated mitochondrial regulation and Alzheimer's disease
Lopez Sanchez, M. I. G., van Wijngaarden, P., & Trounce, I. A. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14554 · Cited by 45
Metadata
- Authors
- van Wijngaarden, P., Hadoux, X., Alwan, M., Keel, S., & Dirani, M.
- Venue
- Clinical & Experimental Ophthalmology
- Publisher
- Wiley
- Published
- 2016-12-19
- Volume
- 45
- Issue
- 1
- Pages
- 54-61
- ISSN
- 1442-6404 (ISSN-L)
- 1442-9071
- OpenAlex
- W2553114530
- Cited by
- 52
- References
- 15
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.